Back to search results

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Relapsed/Refractory Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Henan Cancer Hospital, Zhengzhou, Henan, China

    Contact: Study coordinator (Baijun Fang, Doctor) · fdation@126.com
    Contact: Study coordinator (Yuzhang Liu, Doctor) · hedajay@163.com

  • The First Affiliated Hospital Of Soochow University, Suzhou, Jiangsu, China

    Contact: Study coordinator (Zhengzheng Fu, Doctor) · fuzhengzheng@suda.edu.cn

  • The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital), Xi’an, Shanxi, China

    Contact: Study coordinator (Wanhong Zhao, Doctor) · 13991365406@163.com

  • The Second Affiliated Hospital Zhejiang University School Of Medicine, Hangzhou, Zhejiang, China

    Contact: Study coordinator (Wenbin Qian, Doctor) · qianwenb@hotmail.com
View source on ClinicalTrials.gov(opens in a new tab)